Journal
CANCER LETTERS
Volume 256, Issue 1, Pages 1-24Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2007.03.016
Keywords
tamoxifen; antiestrogen; aromatase inhibitor; fulvestrant; estrogen receptor
Categories
Funding
- NCI NIH HHS [T32 CA009109, R01 CA096846, R01 CA123037, T32 CA009109-29, R01 CA096846-03, R01 CA 096846, T32 CA009686, R01 CA123037-02, R01 CA096846-02, R01 CA096846-04, R01 CA 123037] Funding Source: Medline
Ask authors/readers for more resources
Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer. While these approaches have proven to be beneficial to a large number of patients, both de novo and acquired resistance to these drugs is a significant problem. Recent advances in our understanding of the molecular mechanisms that contribute to resistance have provided a means to begin to predict patient responses to these drugs and develop rational approaches for combining therapeutic agents to circumvent or desensitize the resistant phenotype. Here, we review common mechanisms of antiestrogen resistance and discuss the implications for prediction of response and design of effective combinatorial treatments. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available